All In Biotech

Drug Trial Radar · NCT06211751

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

A Phase Ib Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of TQB3909 Tablets Combined With TQB3702 Tablets in Hematologic Malignancy Subjects.

Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

208

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Dec 2025

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.

Conditions

  • Hematologic Malignancy

Interventions

  • TQB3909 tabletsDrug

    TQB3909 is a protein inhibitor.

  • TQB3702 tabletsDrug

    TQB3702 is a kinase inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicity (DLT)Time frame: Baseline up to 104 weeks
  2. Adverse events (AE)Time frame: Baseline up to 104 weeks
  3. Serious adverse events (SAE)Time frame: Baseline up to 104 weeks
  4. Clinical laboratory abnormalitiesTime frame: Baseline up to 104 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.